Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline

Bryan J. Schneider, Nofisat Ismaila, Joachim Aerts, Caroline Chiles, Megan E. Daly, Frank C. Detterbeck, Jason W.D. Hearn, Sharyn I. Katz, Natasha B. Leighl, Benjamin Levy, Bryan Meyers, Septimiu Murgu, Larissa Nekhlyudov, Edgardo S. Santos, Navneet Singh, Joan Tashbar, David Yankelevitz, Nasser Altorki

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


PURPOSE To provide evidence-based recommendations to practicing clinicians on radiographic imaging and biomarker surveillance strategies after definitive curative-intent therapy in patients with stage I-III non-small-cell lung cancer (NSCLC) and SCLC. METHODS ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, radiology, primary care, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2019. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS The literature search identified 14 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS Patients should undergo surveillance imaging for recurrence every 6 months for 2 years and then annually for detection of new primary lung cancers. Chest computed tomography imaging is the optimal imaging modality for surveillance. Fluorodeoxyglucose positron emission tomography/computed tomography imaging should not be used as a surveillance tool. Surveillance imaging may not be offered to patients who are clinically unsuitable for or unwilling to accept further treatment. Age should not preclude surveillance imaging. Circulating biomarkers should not be used as a surveillance strategy for detection of recurrence. Brain magnetic resonance imaging should not be used for routine surveillance in stage I-III NSCLC but may be used every 3 months for the first year and every 6 months for the second year in patients with stage I-III small-cell lung cancer who have undergone curative-intent treatment.

Original languageEnglish (US)
Pages (from-to)753-766
Number of pages14
JournalJournal of Clinical Oncology
Issue number7
StatePublished - Mar 1 2020
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline'. Together they form a unique fingerprint.

Cite this